Cabaletta Bio's Cell Therapy In Skin Blistering Disorder Shows Favorable Safety Profile


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


  • Cabaletta Bio Inc (NASDAQ: CABA) has announced acute safety data from the first dose cohort of the ongoing DesCAARTes Phase 1 trial of DSG3-CAART for mucosal-dominant pemphigus Vulgaris (mPV).
  • In the first cohort of three patients dosed with DSG3-CAART, there were no clinically relevant adverse events, including cytokine release syndrome or neurotoxicity, during the 8-day acute safety window.
  • Additionally, no dose-limiting toxicities or clinically relevant adverse events were observed in the two patients who have completed more than the full 28-day DLT monitoring period post-infusion.
  • These safety data were observed with an administered dose of 20 million DSG3-CAART cells, without preconditioning and in the presence of circulating anti-DSG3 antibodies.
  • The third patient is scheduled to be evaluated for the presence of DSG3-CAART after the 28-day follow-up period.
  • The trial currently enrolls patients in the second cohort at a treatment dose of 100 million DSG3-CAART cells.
  • Acute safety data for the second and third cohorts are expected in the third and fourth quarters of 2021, respectively.
  • Topline data on target engagement from the first cohort are anticipated during the second half of 2021.
  • The company also reported Q1 2021 fiscal results with an EPS loss of $0.41 higher than $0.33 a year ago.
  • Cash and equivalents of $102.0 million are expected to fund its operating plan through at least the fourth quarter of 2022.
  • Price Action: CABA shares are down 0.04% at $11.13 in the market trading session on the last check Monday.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechEarningsNewsHealth CareGeneralBriefsSkin Disorder